论文部分内容阅读
该书是第一本论述白介素-2临床治疗癌症的专著,由美国新英格兰中心医院血液病学肿瘤学部内科医师Michael B.Atkins和Jame W.Mier二人合编,1993年出版。 1992年5月5日,美国食品和药物管理局批准了白介素-2的临床应用,允许将白介素-2用于治疗转移性肾细胞癌。从此,生物疗法随着白介素-2的临床应用向前迈出了坚实的一步,并成为继手术疗法、放射疗法和化学疗法之后的第四种治疗癌症的有效方法。 1O年前,干扰素的出现,向人们展示了世界上第一种具有抗癌活性的生物分子。干扰素具有直接的抗肿癌活性的生物作用。其抗癌活性体现在它对恶性细胞的生长具有直接影响。与干扰素不同,白介素-2本身对癌细胞并无任何直接影响,而是通过刺激宿主的免疫反应,引发其抗肿瘤活性。目前仅限用于临床治疗转移性肾细胞癌患者。研究证明,白介素-2对其他肿瘤,如黑瘤和淋巴瘤,同样具有活性。
The book is the first monograph on the clinical treatment of interleukin-2 cancer, compiled by Michael B. Atkins and Jame W. Mier, MD, Department of Hematology Oncology, New England Center Hospital, and published in 1993. On May 5, 1992, the U.S. Food and Drug Administration approved the clinical use of interleukin-2, allowing interleukin-2 to be used in the treatment of metastatic renal cell carcinoma. Since then, biotherapy has taken a solid step forward with the clinical use of interleukin-2 and is the fourth effective treatment of cancer after surgery, radiotherapy and chemotherapy. 10 years ago, the emergence of interferon, to show people the world’s first anti-cancer activity of biological molecules. Interferon has a direct biological effect on anti-cancer activity. Its anti-cancer activity is reflected in its direct impact on the growth of malignant cells. Unlike interferons, interleukin-2 itself does not have any direct effect on cancer cells, but rather initiates its anti-tumor activity by stimulating the host’s immune response. Currently only for clinical treatment of patients with metastatic renal cell carcinoma. Studies have shown that interleukin-2 is also active on other tumors, such as melanomas and lymphomas.